Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Dose Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Subcutaneous Doses of CBP-4888 in Hospitalized Participants With Preterm Preeclampsia Receiving Standard of Care, Expectant Management

NCT07282171 is registered in ClinicalTrials.gov with Comanche Biopharma as lead sponsor.

NCT NCT07282171
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07282171 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Dose Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Subcutaneous Doses of CBP-4888 in Hospitalized Participants With Preterm Preeclampsia Receiving Standard of Care, Expectant Management
Lead sponsor
Comanche Biopharma
Phase
Phase 1
Overall status
Recruiting
Start date
February 26, 2025
Completion date
March 31, 2029
Enrollment
60 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

preeclampsia, preterm preeclampsia, sflt1 mediated preterm preeclampsia